Scribd Logo
Upload

Welcome to Scribd!

  • 25 views

    Materi 1

    Uploaded by

    ludhang
    Indonesia has an estimated 1.9% of new TB cases and 12% of previously treated TB cases that are multi-drug resistant. Only 30% of previously treated cases and less than 1% of new cases are tested for drug resistance in Indonesia. The country aims to expand drug resistance surveillance and testing to achieve national coverage by 2015-2016. GeneXpert provides an important tool for rapid diagnosis of drug resistant TB, though challenges remain in scaling up testing and treatment programs in Indonesia.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Materi 1

    Uploaded by

    ludhang
    25 views50 pages
    Indonesia has an estimated 1.9% of new TB cases and 12% of previously treated TB cases that are multi-drug resistant. Only 30% of previously treated cases and less than 1% of new cases are tested for drug resistance in Indonesia. The country aims to expand drug resistance surveillance and testing to achieve national coverage by 2015-2016. GeneXpert provides an important tool for rapid diagnosis of drug resistant TB, though challenges remain in scaling up testing and treatment programs in Indonesia.

    Original Description:

    TB

    Original Title

    MATERI 1

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Indonesia has an estimated 1.9% of new TB cases and 12% of previously treated TB cases that are multi-drug resistant. Only 30% of previously treated cases and less than 1% of new cases are tested for drug resistance in Indonesia. The country aims to expand drug resistance surveillance and testing to achieve national coverage by 2015-2016. GeneXpert provides an important tool for rapid diagnosis of drug resistant TB, though challenges remain in scaling up testing and treatment programs in Indonesia.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    25 views50 pages

    Materi 1

    Uploaded by

    ludhang
    Indonesia has an estimated 1.9% of new TB cases and 12% of previously treated TB cases that are multi-drug resistant. Only 30% of previously treated cases and less than 1% of new cases are tested for drug resistance in Indonesia. The country aims to expand drug resistance surveillance and testing to achieve national coverage by 2015-2016. GeneXpert provides an important tool for rapid diagnosis of drug resistant TB, though challenges remain in scaling up testing and treatment programs in Indonesia.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    You are on page 1of 50

    Photo: Riccardo Venturi

    GLOBAL MDR-TB ERADICATION PROGRAMS

    Setiawan Jati Laksono


    TB Unit

    World Health Organization


    Outline
    1. Global TB situation
    2. Global DR TB Surveillance
    3. Global DR TB response
    4. Five Priority action to address The
    Global MDR TB Crisis
    Indonesia:
    Sub National data only from 2 DRS in
    Central Java 2006 and East Java 2009
    Estimated 1.9% among new and 12% among
    Previously treated TB cases
    Indonesia:
    # 10th with 6,800 cases
    Indonesia:
    1. Only 30% of previously treated and < 1% new cases tested
    2. No national wide DRS surveillance/ survey
    3. Planned for 2015-2016
    Indonesia: 0.03%
    Indonesia: <15% tested in 2013, 30% tested in 2014
    Indonesia: 44%
    9 cases from Indonesia
    Role of GeneXpert for TB Control Program:
    • Xpert MTB/RIF should be used rather than conventional microscopy,
    culture and DST as the initial diagnostic test in adults and children
    suspected of having MDR-TB or HIV associated TB.
    • Xpert MTB/RIF may be used as a follow-on test to microscopy in adults
    and children where MDR-TB and HIV is of lesser concern, especially in
    further testing of smear-negative specimens.
    • Xpert MTB/RIF may be used rather than conventional microscopy and
    culture as the initial diagnostic test in all adults suspected with TB.
    • Xpert MTB/RIF may be used rather than conventional microscopy and
    culture as the initial diagnostic test in all children suspected of having TB
    • Xpert MTB/RIF should be used in preference to conventional microscopy
    and culture as the initial diagnostic test in testing cerebrospinal fluid
    specimens from patients presumed to have TB meningitis
    • Xpert MTB/RIF may be used as a replacement test for usual practice
    (including conventional microscopy, culture, and/or histopathology) for
    testing of specific nonrespiratory specimens (lymph nodes and other
    tissues) from patients presumed to have extrapulmonary TB
    PROMOTE
    REACH
    DETECT
    TREATMENT
    RETAIN
    SUPPORT
    CURE
    PREVENT

    MATUR NUWUN
    Treatment standards:
    Treatment standards:

    You might also like